Major depressive disorder (MDD) is one of the leading causes of disability worldwide, affecting more than 280 million people. While traditional antidepressants have helped millions, about one-third of people with Depression have treatment-resistant Depression (TRD), meaning they’ve tried multiple antidepressants with little or no success. Recent research has shifted attention to a new neurotransmitter system—glutamate—with glutamate Depression treatment leading the charge for the next generation of TRD treatment pathways. We’ll explore what the latest science says about glutamatergic modulators, why esketamine is such a game-changer, and how it can fit into your care journey.
The Shift From Monoamines to Glutamate Depression Treatment
For decades, Depression treatments focused almost exclusively on monoamine neurotransmitters—serotonin, dopamine, and norepinephrine. While these systems play important roles in mood, the monoamine hypothesis never fully explained why Depression develops, nor why antidepressants can take six weeks or more to work. Instead of focusing on monoamine neurotransmitters, glutamatergic modulators—most notably esketamine—work on the brain’s glutamate pathways, helping restore connections and improve brain plasticity
The article “Glutamatergic Modulators for Major Depression: From Theory to Clinical Use” highlights how growing evidence points to glutamate dysfunction in depression. Glutamate is the brain’s most abundant excitatory neurotransmitter. It’s crucial for functions including:
- Synaptic plasticity (the brain’s ability to adapt and rewire).
- Memory and learning.
- Stress response regulation.
Imbalances in glutamate signaling can reduce brain connectivity in regions like the prefrontal cortex and hippocampus—areas vital for mood regulation. Brain imaging studies confirm that patients with Depression often show altered glutamate activity in these regions.
This discovery opened the door to therapies that don’t just increase serotonin levels, but actually repair and regenerate neural connections damaged by chronic stress and Depression.
Ketamine as a Glutamate Treatment for Depression: The Spark That Started It All
The shift towards ketamine as glutamate treatment for Depression began with a groundbreaking study in 2000 showing that intravenous ketamine produced rapid antidepressant effects within hours in patients who hadn’t responded to other treatments. Unlike traditional antidepressants, ketamine didn’t take weeks to work. It also appeared to reduce suicidal thinking more quickly than any previous treatment.
Ketamine works by blocking the NMDA receptor—a type of glutamate receptor—triggering a cascade that boosts AMPA receptor activation, releases brain-derived neurotrophic factor (BDNF), and stimulates synaptogenesis (the growth of new synaptic connections). In simpler terms: ketamine helps the brain rewire itself, potentially reversing some of the biological damage of Depression.
Esketamine: The First FDA-Approved Glutamatergic Antidepressant
However, IV ketamine still posed certain challenges for clinicians and patients alike; it wasn’t FDA-approved for Depression, dosing could be inconsistent, and it required specific infusion centers. That’s where esketamine entered the picture.
Esketamine, the S-enantiomer of ketamine, was developed to provide a safer, more targeted treatment option. In 2019, the FDA approved intranasal esketamine as a glutamate treatment for Depression (under the brand name Spravato®) for adults with TRD.
Key advantages of esketamine as a glutamate treatment for Depression include:
- FDA approval with well-defined dosing protocols.
- Intranasal delivery, making it less invasive than IV infusion.
- Clinic-based supervision for safety and monitoring.
- Proven efficacy in TRD through large phase III trials (e.g., TRANSFORM and SUSTAIN studies)
At Mid City TMS, our certified clinicians guide each patient through treatment sessions in a safe and comfortable setting. Patients self-administer the nasal spray under supervision, then relax in our clinic for about two hours while being monitored.
What the Evidence for Esketamine as Glutamate Depression Treatment Shows: Rapid and Meaningful Relief
According to the review article, esketamine has demonstrated robust and rapid antidepressant effects in both short- and long-term studies.
Clinical Findings of Focusing on Glutamate Depression Treatment:
Shifting the focus of MDD treatment towards glutamate depression treatment options has yielded a few key results in clinical settings:
- Rapid Onset: Many patients experience noticeable improvement within hours to days—much faster than oral antidepressants.
- Symptom Reduction: In pivotal trials, esketamine plus an oral antidepressant led to significantly greater reductions in Depression scores compared to placebo plus oral antidepressant.
- Relapse Prevention: Long-term studies show that continuing esketamine reduces the risk of relapse compared to discontinuation.
- Suicidal Ideation: Some studies suggest esketamine may reduce suicidal thinking more rapidly than conventional options, though this remains an area of active research.
Patients consistently report improvements not only in mood, but also in motivation, energy, and social functioning—domains that matter most in daily life.
Safety, Side Effects, and Monitoring
Esketamine as a glutamate treatment for Depression can represent an empowering choice, but like any medication, it comes with potential side effects. The most common include:
- Dissociation (feeling “spaced out” or detached)
- Dizziness or nausea
- Temporary rise in blood pressure
- Fatigue or sedation
Because of these effects, esketamine as glutamate treatment for Depression is only available through certified treatment centers like Mid City TMS, under the FDA’s REMS (Risk Evaluation and Mitigation Strategy) program. Patients must remain in the clinic for at least two hours after each session, and cannot drive themselves home. This structured monitoring ensures safety while maximizing treatment benefits.
Esketamine vs. TMS: Complementary Options
While this article focuses on esketamine, it’s worth mentioning another advanced treatment: Transcranial Magnetic Stimulation (TMS). While Esketamine acts biologically on brain chemistry and neural plasticity, TMS is non-invasive, using magnetic pulses to stimulate brain circuits involved in mood regulation.
Both are FDA-approved for treatment-resistant Depression. Some patients prefer a non-medication approach and choose TMS, while others opt for esketamine. In some cases, patients may benefit from both therapies, either sequentially or in combination. At Mid City TMS, we offer both treatments and tailor recommendations to each patient’s unique needs.
Why the Patient Experience of Glutamatergic Modulators Matters
Beyond symptom checklists, patient-reported outcomes are especially critical. In real-world practice, patients receiving esketamine often describe:
- A “lifting” of emotional, physical, and mental heaviness.
- A renewed ability to engage in daily tasks.
- Improved energy and concentration.
- Reconnection with family, friends, and hobbies.
These experiences align with our own patients’ experiences at Mid City TMS. While no treatment is a “cure,” esketamine often brings meaningful improvements in quality of life, sometimes after years of frustration with standard antidepressants.
The Future of Glutamatergic Therapies
Esketamine is only the beginning. The review notes ongoing research into other glutamatergic modulators, such as:
- Rapastinel (an NMDA receptor partial agonist)
- Apimostinel
- NR2B antagonists
- AMPA receptor modulators
While these modulators are still under investigation, esketamine represents the first wave of clinically available options. As research progresses, more therapies targeting glutamate could broaden our ability to personalize treatment for Depression.
Unlocking a New Chapter in Depression Treatment With Mid City TMS
For decades, patients with treatment-resistant Depression were left with few alternatives after exhausting standard medications. The development of esketamine nasal spray marks a major milestone—a treatment that works differently, faster, and often more effectively for those who need it most.
At Mid City TMS, we are proud to provide esketamine (Spravato®) treatment, alongside TMS, as part of our mission to offer cutting-edge, evidence-based care. We’ve seen firsthand how esketamine therapy, backed by decades of research and now approved as a monotherapy, represents one of the most exciting breakthroughs in psychiatry yet.
If you or a loved one has struggled with Depression that hasn’t improved with standard antidepressants, we invite you to explore whether esketamine might be the right next step. Contact Mid City TMS today to schedule a consultation and learn how esketamine treatment can help you overcome MDD.
Sources
- McIntyre, R. S., et al. (2024). Glutamatergic Modulators for Major Depression: From Theory to Clinical Use. Front Psychiatry. PMC11486832
- Daly, E. J., et al. (2019). Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant in treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry.
- Popova, V., et al. (2019). Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: A randomized double-blind active-controlled study. Am J Psychiatry.
- U.S. Food and Drug Administration. (2019). FDA approves new nasal spray medication for treatment-resistant depression.
